Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

Mustafa Ozguroglu,Ahmet Sezer,Saadettin Kilickap,Mahmut Gumus,Igor Bondarenko,Miranda Gogishvili,Haci Mehmet Türk,Irfan Cicin,Dmitry Bentsion,Oleg Gladkov,Philip Clingan,Virote Sriuranpong,Naiyer A. Rizvi,Jennifer McGinniss,Jean-Francois Pouliot,S. Lee,Frank Seebach,Israel Lowy,Giuseppe Gullo,P Rietschel

Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

2021

9085Background: In the Phase 3, EMPOWER-Lung 1 study, cemiplimab monotherapy provided significant survival benefit and an acceptable safety profile vs chemotherapy in patients with advanced NSCLC a...

Keywords:

PD-L1
in patient
Programmed cell death ligand 1
Medicine
Subgroup analysis
Oncology
Chemotherapy
first line
Lung
Internal medicine
non-small cell lung cancer (NSCLC)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations